Rebeiz, A. G., Pieper, K. S., O’Shea, J. C., Gilchrist, I. C., Chandler, B., Slater, J., … Tcheng, J. E. (2001). 16 to 18-hour infusions of eptifibatide seem optimal in reducing ischemic complications following percutaneous coronary intervention. CIRCULATION, 104(17), 386–386.

Rebeiz, A. G., K. S. Pieper, J. C. O’Shea, I. C. Gilchrist, B. Chandler, J. Slater, J. B. Muhlestein, et al. “16 to 18-hour infusions of eptifibatide seem optimal in reducing ischemic complications following percutaneous coronary intervention.” CIRCULATION 104, no. 17 (October 23, 2001): 386–386.

Rebeiz AG, Pieper KS, O’Shea JC, Gilchrist IC, Chandler B, Slater J, et al. 16 to 18-hour infusions of eptifibatide seem optimal in reducing ischemic complications following percutaneous coronary intervention. CIRCULATION. 2001 Oct 23;104(17):386–386.

Rebeiz, A. G., et al. “16 to 18-hour infusions of eptifibatide seem optimal in reducing ischemic complications following percutaneous coronary intervention.” CIRCULATION, vol. 104, no. 17, LIPPINCOTT WILLIAMS & WILKINS, Oct. 2001, pp. 386–386.

Rebeiz AG, Pieper KS, O’Shea JC, Gilchrist IC, Chandler B, Slater J, Muhlestein JB, Lorenz TJ, Joseph D, Kitt MM, Tcheng JE. 16 to 18-hour infusions of eptifibatide seem optimal in reducing ischemic complications following percutaneous coronary intervention. CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS; 2001 Oct 23;104(17):386–386.